Taken together, these data demonstrated that TRIP13 promoted gastric cell tumorigenesis through the JAK/STAT and p53 signaling pathways, and they identify a promising therapeutic target in the treatment of gastric cancer. This evidence concerns the gene TRIP13 and gastric cancer.